Impax Asset Management Group plc acquired a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,381 shares of the company's stock, valued at approximately $662,000.
Several other large investors have also modified their holdings of the stock. Jones Financial Companies Lllp raised its holdings in Cencora by 212.4% during the 4th quarter. Jones Financial Companies Lllp now owns 2,390 shares of the company's stock worth $537,000 after buying an additional 1,625 shares during the period. SBI Securities Co. Ltd. purchased a new stake in shares of Cencora in the fourth quarter valued at $30,000. M&T Bank Corp lifted its holdings in shares of Cencora by 4.3% in the fourth quarter. M&T Bank Corp now owns 15,592 shares of the company's stock valued at $3,503,000 after purchasing an additional 636 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Cencora in the fourth quarter valued at $31,936,000. Finally, Candriam S.C.A. lifted its holdings in shares of Cencora by 2.2% in the fourth quarter. Candriam S.C.A. now owns 8,040 shares of the company's stock valued at $1,806,000 after purchasing an additional 176 shares in the last quarter. 97.52% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the company. Morgan Stanley set a $288.00 target price on Cencora in a report on Tuesday, April 15th. Citigroup increased their target price on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $274.00 to $337.00 in a report on Tuesday, June 3rd. Robert W. Baird upped their price target on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Finally, Bank of America upped their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $306.33.
Check Out Our Latest Stock Analysis on Cencora
Cencora Stock Up 2.1%
Cencora stock traded up $6.20 during mid-day trading on Monday, hitting $302.43. 1,597,776 shares of the company's stock were exchanged, compared to its average volume of 1,507,152. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. The stock has a market cap of $58.62 billion, a P/E ratio of 35.08, a P/E/G ratio of 1.47 and a beta of 0.57. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The stock has a 50 day moving average of $291.12 and a two-hundred day moving average of $267.80.
Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The business's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $3.80 earnings per share. As a group, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.
Cencora Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.73%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio is currently 25.52%.
Insider Activity at Cencora
In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the transaction, the chief executive officer directly owned 47,582 shares of the company's stock, valued at $13,766,900.06. The trade was a 9.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the sale, the chairman directly owned 311,913 shares in the company, valued at $91,271,982.06. The trade was a 4.47% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,127 shares of company stock worth $9,812,296. Company insiders own 10.80% of the company's stock.
Cencora Company Profile
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles

Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report